Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. - Wikidata - awgldk - TriplyDB

Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

http://www.wikidata.org/entity/Q33860902

about

Anti-vascular endothelial growth factor for diabetic macular oedema Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study Updates on the Clinical Trials in Diabetic Macular Edema Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss The Vitreomacular Interface in Diabetic Retinopathy Anti-VEGF Therapy and the Retina: An Update Individualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?Targeting inflammation in diabetes: Newer therapeutic options New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel A review of therapies for diabetic macular oedema and rationale for combination therapy Treatment of diabetic retinopathy: Recent advances and unresolved challenges Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory Update on corticosteroids for diabetic macular edema Recent developments in laser treatment of diabetic retinopathy Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy.Effect of intravitreal anti-vascular endothelial growth factor therapy on the risk of arterial thromboembolic events: a meta-analysis Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results.Diabetic macular edema: Current management 2013 Clinical trials on corticosteroids for diabetic macular edema New Therapeutic Approaches in Diabetic Retinopathy.Cost-effectiveness of treatment of diabetic macular edema.A Review of Ranibizumab for the Treatment of Diabetic Retinopathy.Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema Efficiency and safety of laser photocoagulation with or without intravitreal ranibizumab for treatment of diabetic macular edema: a systematic review and Meta-analysis 12-month results of the standardised combination therapy for diabetic macular oedema: intravitreal bevacizumab and navigated retinal photocoagulation Comparison of grid laser, intravitreal triamcinolone, and intravitreal bevacizumab in the treatment of diffuse diabetic macular edema.Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema.Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates.Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema.Ranibizumab: in diabetic macular oedema.Combination therapy for diabetic macular edema.Corticosteroid use for diabetic macular edema: old fad or new trend?Intravitreal ranibizumab (lucentis) for the treatment of diabetic macular edema: a systematic review and meta-analysis of randomized clinical control trials.Novel atypical PKC inhibitors prevent vascular endothelial growth factor-induced blood-retinal barrier dysfunction The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review.Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab.Revolution to a new standard treatment of diabetic macular edema

P2860

Q24193083-45CEB4E4-5632-4701-8570-0F6A7B788C76 Q24202071-D10CA23C-E7EA-4973-B0BE-B088FC6C033D Q24658546-9513011C-2B51-4C25-92AD-BD35A7D4DBB4 Q26767100-F2877F69-332D-4C9D-9A81-9240E417CC2C Q26775552-586BA07F-9C42-42F5-8722-4BBFC12CF024 Q26783404-B0A9B5E3-5EA7-4755-966D-1CC5CE1E5CDF Q26784605-34CA36A7-0C5B-4690-939D-30348AB9566F Q26799492-81B37CD3-B884-4A1C-B9FA-ABC7A33C5133 Q26852726-F8269337-B98E-4F7D-860E-160115918387 Q26853239-E2FD1B97-4D62-4917-8453-8311E19AB5F7 Q27008325-8D15BBDA-5DD4-4656-856F-18E9AC62C337 Q28067491-BB584E3A-1160-4C58-B273-A65B45D1F7E0 Q28070894-3234C969-DDCA-4C23-9121-72076E03DBE3 Q28074846-2E6D4180-A2A9-44CF-8871-311A4AB1F722 Q28084139-6AD0603C-38F9-41C8-93F7-AA1C5605959D Q28292764-F644F9E9-4BFD-4C22-9D34-92054145BA0C Q30244247-00C344F6-1C08-418E-895D-BC5DC3F0F915 Q31076710-1E09E72B-16B8-4DF7-8022-ED8E17284665 Q31100308-CE58D9C4-1573-48AC-B0CA-6DF05873F273 Q31146850-19C8B093-9AD8-4687-BA78-9451B6F4AAC7 Q31146864-2E17D0F5-FBD8-4821-8ACA-57273C41228E Q33583037-CB1CCB48-8927-440A-9ED4-3F9DC6C8736A Q33606611-9CF346C7-A173-4C9D-A949-654EC0E9D359 Q33740152-91EC90E7-8C9B-4F11-850E-250712028ED4 Q33759212-C50FF89C-1E49-40A3-8002-24D202EB9EBD Q33912485-458A3D42-39E8-44C2-A5A3-A6917DE034F0 Q33956443-8EAF8CB5-DC43-4771-8ED7-914703F45BF3 Q34011604-86DEB1C5-CBC2-4FCA-A6BB-A6D5F66C7210 Q34037627-91160BD7-3843-4F0F-B18D-0639D295BFB6 Q34062356-CB4FE484-6238-4937-A8F3-FE823FFEAEEB Q34062494-0CA31F95-E0EB-4A2B-9603-DE7622F5D1A3 Q34139793-51841A0F-D11A-42B0-BA06-34915025D067 Q34166795-466608BB-216E-4AEB-81D6-4EA2BABD5340 Q34241921-4B55BE97-FA80-4901-9AEA-B5D4D7AE24C8 Q34267270-57F5622A-2253-47C1-B4BC-BBDE66D86264 Q34282654-98F8FB8C-3188-47CC-8C80-21683E271E3B Q34313113-D23BDE65-FF08-415D-A2AD-85CF78BC8605 Q34378757-2C5817C5-8C2F-4DF3-A71B-A3C7F47331AA Q34410772-1A73785B-FEEB-4294-9F2B-5DB98E480C57 Q34461573-19FD568B-AC67-4184-8022-10D4E2F94569

P2860

Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

http://www.wikidata.org/entity/Q33860902

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Expanded 2-year follow-up of r ...... er for diabetic macular edema.

@ast

Expanded 2-year follow-up of r ...... er for diabetic macular edema.

@en

type

label

Expanded 2-year follow-up of r ...... er for diabetic macular edema.

@ast

Expanded 2-year follow-up of r ...... er for diabetic macular edema.

@en

prefLabel

Expanded 2-year follow-up of r ...... er for diabetic macular edema.

@ast

Expanded 2-year follow-up of r ...... er for diabetic macular edema.

@en

P1433

Q33860902-6E8E2BE3-D7B7-47AF-8D60-380DD9F39EE3

P1476

Q33860902-213AE398-F54C-4AA6-A177-9239C36861A7

P2093

Q33860902-1A0A99B1-5646-40C0-AFA9-EDBC94D4D4C6

Q33860902-2CFC4AAC-D53C-4ACD-BCA3-55C901A2CCBE

Q33860902-59EB2C21-0B72-4397-9489-7E06D0ED2539

Q33860902-5C4CEE9A-4115-448A-AB5D-63CD1AA435D3

Q33860902-5F64465F-3B63-4642-B414-32AB5DE27003

Q33860902-6F4483DC-8218-421F-8360-4E2D59CA7940

Q33860902-8953A109-E018-4D70-8BE7-0346556DBFFF

Q33860902-A5711BB2-B9BC-469E-AC85-55E051456D83

Q33860902-BDDB6D4B-0463-4CD8-9B1E-31CC70DB1451

Q33860902-C1A7FC3A-BE1F-4123-8436-76CD0E736626

P2860

Q33860902-449FE13E-341C-449E-AED9-9C324253C4DD

Q33860902-BA84CCDE-FBDC-48A8-8B59-1A4FB6C33F9E

Q33860902-DC65FD51-24B3-4D98-BC45-928DC0572C93

P304

Q33860902-934D051E-CF78-4058-892A-F6AA7CF2D663

P31

Q33860902-C86BEB7D-443F-49F5-8CC3-010E24AC8014

P356

Q33860902-35AF07A0-5236-4C99-B491-DCBF6C31C1EA

P433

Q33860902-0C92B371-EC42-4FB0-BF13-1EBFB4ADC391

P478

Q33860902-121589E7-24B1-4E7D-8180-C9F0F5AEEE7B

P577

Q33860902-99D83B51-B4D4-4AF6-8960-CC1BB0434AFB

P5875

Q33860902-FFC8E2F0-A47F-453C-92CF-66A6CE9DEC5A

P698

Q33860902-9764D0B7-823D-4514-ACF1-48E013049983

P932

Q33860902-D38F9FE4-6CC7-46B6-94F4-01FC170AE66D

P356

J.OPHTHA.2010.12.033

P1433

P1476

Expanded 2-year follow-up of r ...... er for diabetic macular edema.

@en

P2093

Adam R Glassman

http://www.w3.org/2001/XMLSchema#string

Cynthia R Stockdale

http://www.w3.org/2001/XMLSchema#string

Diabetic Retinopathy Clinical Research Network

http://www.w3.org/2001/XMLSchema#string

Frederick L Ferris

http://www.w3.org/2001/XMLSchema#string

Haijing Qin

http://www.w3.org/2001/XMLSchema#string

Ingrid U Scott

http://www.w3.org/2001/XMLSchema#string

Jennifer K Sun

http://www.w3.org/2001/XMLSchema#string

Michael J Elman

http://www.w3.org/2001/XMLSchema#string

Neil M Bressler

http://www.w3.org/2001/XMLSchema#string

Roy W Beck

http://www.w3.org/2001/XMLSchema#string

P2860

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

P304

609-614

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.OPHTHA.2010.12.033

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50988181

http://www.w3.org/2001/XMLSchema#string

P698

21459214

http://www.w3.org/2001/XMLSchema#string

P932

3096445

http://www.w3.org/2001/XMLSchema#string